A new trading day began on Monday, with Lineage Cell Therapeutics Inc (AMEX: LCTX) stock price down -8.19% from the previous day of trading, before settling in for the closing price of $0.49. LCTX’s price has ranged from $0.47 to $1.56 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 120.15%. Meanwhile, its annual earnings per share averaged -4.76%. With a float of $227.36 million, this company’s outstanding shares have now reached $228.36 million.
Let’s determine the extent of company efficiency that accounts for 77 employees. In terms of profitability, gross margin is 94.64%, operating margin of -226.11%, and the pretax margin is -195.62%.
Lineage Cell Therapeutics Inc (LCTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Lineage Cell Therapeutics Inc is 0.44%, while institutional ownership is 51.10%. The most recent insider transaction that took place on Jan 27 ’25, was worth 6,000,000. In this transaction Director of this company bought 7,894,737 shares at a rate of $0.76, taking the stock ownership to the 49,560,992 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Financial Officer bought 15,000 for $0.59, making the entire transaction worth $8,850. This insider now owns 25,500 shares in total.
Lineage Cell Therapeutics Inc (LCTX) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -4.76% per share during the next fiscal year.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Trading Performance Indicators
Here are Lineage Cell Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.86.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.10, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.06 in one year’s time.
Technical Analysis of Lineage Cell Therapeutics Inc (LCTX)
Looking closely at Lineage Cell Therapeutics Inc (AMEX: LCTX), its last 5-days average volume was 1.36 million, which is a drop from its year-to-date volume of 1.8 million. As of the previous 9 days, the stock’s Stochastic %D was 20.18%. Additionally, its Average True Range was 0.04.
During the past 100 days, Lineage Cell Therapeutics Inc’s (LCTX) raw stochastic average was set at 0.17%, which indicates a significant decrease from 0.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.70% in the past 14 days, which was lower than the 101.89% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5909, while its 200-day Moving Average is $0.7633. However, in the short run, Lineage Cell Therapeutics Inc’s stock first resistance to watch stands at $0.4748. Second resistance stands at $0.4981. The third major resistance level sits at $0.5101. If the price goes on to break the first support level at $0.4395, it is likely to go to the next support level at $0.4275. Should the price break the second support level, the third support level stands at $0.4042.
Lineage Cell Therapeutics Inc (AMEX: LCTX) Key Stats
With a market capitalization of 103.13 million, the company has a total of 228,356K Shares Outstanding. Currently, annual sales are 9,500 K while annual income is -18,610 K. The company’s previous quarter sales were 2,870 K while its latest quarter income was -3,270 K.
